Clinical data for the foremost-ever RET inhibitor, selpercatinib (Retevmo), hide efficacy in two groups of patients with most cancers ? those with RET fusion–sure non–minute…
Clinical data for the foremost-ever RET inhibitor, selpercatinib (Retevmo), hide efficacy in two groups of patients with most cancers ? those with RET fusion–sure non–minute…